Evidence map›Paper›PMID 27144218›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2016

Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma.

Scott Montgomery, Mohammadhossein Hajiebrahimi, Sarah Burkill, Jan Hillert, Tomas Olsson, Shahram Bahmanyar

Open access · goldAbstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Scott MontgomeryClinical Epidemiology and Biostatistics (S.M.), School of Medical Sciences, Örebro University, Sweden; Department of Epidemiology and Public Health (S.M.), University College London, UK; Clinical Epidemiology Unit (S.M., M.H.H., S. Burkill, S. Bahmanyar) and Centre for Pharmacoepidemiology (S. Bahmanyar), Department of Medicine, Solna, Karolinska Institutet; Department of Neurology (J.H., T.O.), Karolinska University Hospital Huddinge, Stockholm; Neuroimmunology Unit (J.H.), Department of Clinical Neuroscience and Centre for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden; and Faculty of Medicine (S. Bahmanyar), Golestan University of Medical Sciences, Gorgan, Iran.
Mohammadhossein HajiebrahimiClinical Epidemiology and Biostatistics (S.M.), School of Medical Sciences, Örebro University, Sweden; Department of Epidemiology and Public Health (S.M.), University College London, UK; Clinical Epidemiology Unit (S.M., M.H.H., S. Burkill, S. Bahmanyar) and Centre for Pharmacoepidemiology (S. Bahmanyar), Department of Medicine, Solna, Karolinska Institutet; Department of Neurology (J.H., T.O.), Karolinska University Hospital Huddinge, Stockholm; Neuroimmunology Unit (J.H.), Department of Clinical Neuroscience and Centre for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden; and Faculty of Medicine (S. Bahmanyar), Golestan University of Medical Sciences, Gorgan, Iran.
Sarah BurkillClinical Epidemiology and Biostatistics (S.M.), School of Medical Sciences, Örebro University, Sweden; Department of Epidemiology and Public Health (S.M.), University College London, UK; Clinical Epidemiology Unit (S.M., M.H.H., S. Burkill, S. Bahmanyar) and Centre for Pharmacoepidemiology (S. Bahmanyar), Department of Medicine, Solna, Karolinska Institutet; Department of Neurology (J.H., T.O.), Karolinska University Hospital Huddinge, Stockholm; Neuroimmunology Unit (J.H.), Department of Clinical Neuroscience and Centre for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden; and Faculty of Medicine (S. Bahmanyar), Golestan University of Medical Sciences, Gorgan, Iran.
Jan HillertClinical Epidemiology and Biostatistics (S.M.), School of Medical Sciences, Örebro University, Sweden; Department of Epidemiology and Public Health (S.M.), University College London, UK; Clinical Epidemiology Unit (S.M., M.H.H., S. Burkill, S. Bahmanyar) and Centre for Pharmacoepidemiology (S. Bahmanyar), Department of Medicine, Solna, Karolinska Institutet; Department of Neurology (J.H., T.O.), Karolinska University Hospital Huddinge, Stockholm; Neuroimmunology Unit (J.H.), Department of Clinical Neuroscience and Centre for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden; and Faculty of Medicine (S. Bahmanyar), Golestan University of Medical Sciences, Gorgan, Iran.
Tomas OlssonClinical Epidemiology and Biostatistics (S.M.), School of Medical Sciences, Örebro University, Sweden; Department of Epidemiology and Public Health (S.M.), University College London, UK; Clinical Epidemiology Unit (S.M., M.H.H., S. Burkill, S. Bahmanyar) and Centre for Pharmacoepidemiology (S. Bahmanyar), Department of Medicine, Solna, Karolinska Institutet; Department of Neurology (J.H., T.O.), Karolinska University Hospital Huddinge, Stockholm; Neuroimmunology Unit (J.H.), Department of Clinical Neuroscience and Centre for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden; and Faculty of Medicine (S. Bahmanyar), Golestan University of Medical Sciences, Gorgan, Iran.
Shahram BahmanyarClinical Epidemiology and Biostatistics (S.M.), School of Medical Sciences, Örebro University, Sweden; Department of Epidemiology and Public Health (S.M.), University College London, UK; Clinical Epidemiology Unit (S.M., M.H.H., S. Burkill, S. Bahmanyar) and Centre for Pharmacoepidemiology (S. Bahmanyar), Department of Medicine, Solna, Karolinska Institutet; Department of Neurology (J.H., T.O.), Karolinska University Hospital Huddinge, Stockholm; Neuroimmunology Unit (J.H.), Department of Clinical Neuroscience and Centre for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden; and Faculty of Medicine (S. Bahmanyar), Golestan University of Medical Sciences, Gorgan, Iran.
Karolinska University Hospital · SEKarolinska Institutet · SEUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine whether there is an association between multiple sclerosis (MS) and young-adult-onset Hodgkin lymphoma (YAHL) as this will signal etiologic similarities relevant both to inherited characteristics and environmental exposures in childhood.

methodsSwedish general population registers identified a cohort of 29,617 with an MS diagnosis between 1968 and 2012, matched with a cohort of 296,164 without MS. Cox regression was used to assess the association of MS with subsequent YAHL (defined as onset between ages 15 and 39 years; n = 20), with adjustment, for age/period, sex, county of residence, and level of education.

resultsThe adjusted hazard ratio (and 95% confidence interval) for the association of MS with YAHL is 3.30 (1.01-10.73), resulting from 4 and 16 events in the MS and non-MS cohorts, respectively. All 4 of the YAHL diagnoses in MS occurred in women, and the association of MS with YAHL has a hazard ratio of 4.04 (1.17-13.94) among women. There was no notable association of MS with older-onset Hodgkin lymphoma.

conclusionThere may be common risks for YAHL and MS, consistent with an etiologic role in MS for early-life exposures, such as to infectious agents.

Identifiers

PMID27144218
PMCPMC4841639
OpenAlexW2341171025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.